Related Experiment Video
Updated: Apr 1, 2026

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods
Published on: September 10, 2016
Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion.
Martin H Floch1, W Allan Walker, Mary Ellen Sanders
1*Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT †Harvard Medical School ‡Mucosal Immunology and Biology Research Center, Massachusetts General Hospital for Children, Boston ††Department of Transplantation, Lahey Hospital and Medical Center, Burlington, MA §Dairy & Food Culture Technologies, International Scientific Association of Probiotics and Prebiotics (ISAPP), Sacramento **Department of Medicine, University of California, San Diego, San Diego, CA ∥Departments of Internal Medicine, Academic Medical Center and VUmC, Amsterdam, The Netherlands ¶Wallenberg Laboratory, Gothenborg University, Gothenburg, Sweden #Minnesota Gastroenterology P.A., Minnesota, MN ‡‡Pediatric Liver & Liver Transplant, Gastroenterology/Transplantation, Phoenix Children's Hospital ∥∥Mayo Clinic, Phoenix §§Department of Pediatrics, University of Arizona, Tucson, AZ ¶¶Department of Translational Medical Sciences, Section of Pediatrics, University of Naples Federico II, Naples ##Clinical Hepato-Gastroenterology Unit, Division of Gastroenterology & Digestive Endoscopy, S. Raffaele University Hospital, Milano, Italy ***Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada †††Department of Gastroenterology, University of North Carolina School of Medicine, Chapel Hill, NC ‡‡‡The Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist Hospital, Houston, TX §§§Department of Medicine, Weill Cornell Medical College, New York ∥∥∥Department of Medicine and Surgery, Division of Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
This consensus report updates probiotic use guidelines for conditions like necrotizing enterocolitis and liver disease. Recommendations are rated A, B, or C for clinical application.
Area of Science:
- Gastroenterology and Hepatology
- Microbiology
Background:
- The 4th Triennial Yale/Harvard Workshop convened experts to establish consensus-based probiotic recommendations.
- This update builds upon previous guidelines published in 2006, 2008, and 2011.
- The scope now includes recommendations for liver disease, alongside established areas.
Framework:
- Recommendations are categorized using an A, B, or C rating system.
- This framework facilitates clinical decision-making regarding probiotic interventions.
- The ratings reflect the strength of evidence and expert consensus.
Implementation:
- Guidance is provided for the use of probiotics in pediatric and adult conditions.
- Specific conditions covered include necrotizing enterocolitis, childhood diarrhea, inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile diarrhea.
- New recommendations address the application of probiotics in liver disease management.
Implications:
- These updated recommendations aim to standardize and optimize the clinical use of probiotics.
- The inclusion of liver disease broadens the applicability of probiotic guidelines.
- This consensus serves as a vital resource for healthcare professionals managing gastrointestinal and liver disorders.
Related Concept Videos
Probiotics
Microbes in the Production of Fermented Foods
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Real Time RT-PCR
The real-time quantification of the number of amplified products is...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

